Hsbc Holdings PLC Purchases New Shares in Xencor, Inc. $XNCR

Hsbc Holdings PLC bought a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 125,482 shares of the biopharmaceutical company’s stock, valued at approximately $2,083,000.

A number of other hedge funds also recently made changes to their positions in XNCR. Johnson & Johnson bought a new position in Xencor during the 2nd quarter worth $12,043,798. Jefferies Financial Group Inc. raised its position in shares of Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after purchasing an additional 620,440 shares during the period. BlackRock Inc. bought a new position in shares of Xencor in the 2nd quarter worth $219,785,000. DCF Advisers LLC acquired a new stake in Xencor in the 2nd quarter valued at $1,670,000. Finally, Primecap Management Co. CA acquired a new stake in Xencor in the 2nd quarter valued at $163,919,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada upped their target price on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Finally, Cantor Fitzgerald upped their price objective on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xencor currently has an average rating of “Hold” and a consensus price target of $24.86.

Xencor Price Performance

NASDAQ:XNCR opened at $26.06 on Monday. The stock has a market cap of $1.94 billion, a P/E ratio of -12.01 and a beta of 0.85. The business’s 50-day moving average price is $19.80 and its two-hundred day moving average price is $14.79. Xencor, Inc. has a twelve month low of $7.83 and a twelve month high of $30.61.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The business had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. Xencor’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the firm posted ($0.41) earnings per share. On average, equities research analysts expect that Xencor, Inc. will post -3 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.